XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Net Sales and Operating Earnings by Segment | The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
|  | Net Sales to External Customers |  | Cost of Products Sold |  | Research and Development |  | Selling, General and Administrative |  | Operating Earnings
|  | Three Months Ended June 30, |  | Three Months Ended June 30, |  | Three Months Ended June 30, |  | Three Months Ended June 30, |  | Three Months Ended June 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 1,383 |  |  | $ | 1,294 |  |  | $ | (631) |  |  | $ | (591) |  |  | $ | (43) |  |  | $ | (44) |  |  | $ | (363) |  |  | $ | (344) |  |  | $ | 346 |  |  | $ | 315 |
Nutritionals |  | 2,212 |  |  | 2,150 |  |  | (1,155) |  |  | (1,148) |  |  | (54) |  |  | (53) |  |  | (585) |  |  | (576) |  |  | 418 |  |  | 373 |
Diagnostics |  | 2,173 |  |  | 2,195 |  |  | (1,224) |  |  | (1,203) |  |  | (154) |  |  | (162) |  |  | (423) |  |  | (400) |  |  | 372 |  |  | 430 |
Medical Devices |  | 5,369 |  |  | 4,734 |  |  | (1,758) |  |  | (1,627) |  |  | (430) |  |  | (379) |  |  | (1,385) |  |  | (1,221) |  |  | 1,796 |  |  | 1,507 |
Total |  | $ | 11,137 |  |  | $ | 10,373 |  |  | $ | (4,768) |  |  | $ | (4,569) |  |  | $ | (681) |  |  | $ | (638) |  |  | $ | (2,756) |  |  | $ | (2,541) |  |  | $ | 2,932 |  |  | $ | 2,625 |
Other |  | 5 |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 11,142 |  |  | $ | 10,377 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate functions and plan benefit costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (65) |  |  | (80) |
Net interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (50) |  |  | (58) |
Share-based compensation (a) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (142) |  |  | (141) |
Amortization of Intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (420) |  |  | (471) |
Other, net (b) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (105) |  |  | (268) |
Earnings before Taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 2,150 |  |  | $ | 1,607 |
|  | Net Sales to External Customers |  | Cost of Products Sold |  | Research and Development |  | Selling, General and Administrative |  | Operating Earnings
|  | Six Months Ended June 30, |  | Six Months Ended June 30, |  | Six Months Ended June 30, |  | Six Months Ended June 30, |  | Six Months Ended June 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 2,643 |  |  | $ | 2,520 |  |  | $ | (1,200) |  |  | $ | (1,175) |  |  | $ | (85) |  |  | $ | (85) |  |  | $ | (714) |  |  | $ | (678) |  |  | $ | 644 |  |  | $ | 582 |
Nutritionals |  | 4,358 |  |  | 4,218 |  |  | (2,279) |  |  | (2,236) |  |  | (106) |  |  | (105) |  |  | (1,161) |  |  | (1,127) |  |  | 812 |  |  | 750 |
Diagnostics |  | 4,227 |  |  | 4,409 |  |  | (2,376) |  |  | (2,391) |  |  | (305) |  |  | (317) |  |  | (815) |  |  | (797) |  |  | 731 |  |  | 904 |
Medical Devices |  | 10,264 |  |  | 9,187 |  |  | (3,356) |  |  | (3,174) |  |  | (831) |  |  | (747) |  |  | (2,672) |  |  | (2,399) |  |  | 3,405 |  |  | 2,867 |
Total |  | $ | 21,492 |  |  | $ | 20,334 |  |  | $ | (9,211) |  |  | $ | (8,976) |  |  | $ | (1,327) |  |  | $ | (1,254) |  |  | $ | (5,362) |  |  | $ | (5,001) |  |  | $ | 5,592 |  |  | $ | 5,103 |
Other |  | 8 |  |  | 7 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 21,500 |  |  | $ | 20,341 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate functions and plan benefit costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (93) |  |  | (146) |
Net interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (99) |  |  | (119) |
Share-based compensation (a) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (431) |  |  | (445) |
Amortization of Intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (840) |  |  | (943) |
Other, net (b) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (201) |  |  | (407) |
Earnings before Taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 3,928 |  |  | $ | 3,043 |
______________________________________
(a) | Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) | Other, net for the three and six months ended June 30, 2025 and 2024 includes charges related to restructurings, fair value adjustments to contingent consideration and integration costs related to business combinations. Other, net for the six months ended June 30, 2025 and 2024 also includes impairment charges related to various investments. Other, net for the three and six months ended June 30, 2024 also includes charges related to the impairment of IPR&D assets, as well as a loss on the divestiture of a non-core business.
Schedule of Depreciation, Additions to Property and Equipment, and Total Assets by Segment |
|  | Depreciation |  | Additions to Property and Equipment
|  | Three Months Ended June 30, |  | Three Months Ended June 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 25 |  |  | $ | 24 |  |  | $ | 39 |  |  | $ | 37 |
Nutritionals |  | 44 |  |  | 39 |  |  | 81 |  |  | 103 |
Diagnostics |  | 135 |  |  | 129 |  |  | 166 |  |  | 169 |
Medical Devices |  | 94 |  |  | 87 |  |  | 145 |  |  | 158 |
Total Reportable Segments |  | 298 |  |  | 279 |  |  | 431 |  |  | 467 |
Other |  | 59 |  |  | 55 |  |  | 62 |  |  | 68 |
Total |  | $ | 357 |  |  | $ | 334 |  |  | $ | 493 |  |  | $ | 535 |
|  | Depreciation |  | Additions to Property and Equipment
|  | Six Months Ended June 30, |  | Six Months Ended June 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 48 |  |  | $ | 48 |  |  | $ | 72 |  |  | $ | 66 |
Nutritionals |  | 86 |  |  | 78 |  |  | 160 |  |  | 176 |
Diagnostics |  | 261 |  |  | 258 |  |  | 301 |  |  | 292 |
Medical Devices |  | 182 |  |  | 174 |  |  | 301 |  |  | 293 |
Total Reportable Segments |  | 577 |  |  | 558 |  |  | 834 |  |  | 827 |
Other |  | 116 |  |  | 109 |  |  | 122 |  |  | 117 |
Total |  | $ | 693 |  |  | $ | 667 |  |  | $ | 956 |  |  | $ | 944 |
Schedule of Reconciliation of Segment Assets to Total Assets |
|  | Total Assets
|  | As of June 30, |  | As of December 31,
(in millions) |  | 2025 |  | 2024
Established Pharmaceuticals |  | $ | 3,732 |  |  | $ | 3,087 |
Nutritionals |  | 4,910 |  |  | 4,404 |
Diagnostics |  | 8,177 |  |  | 7,678 |
Medical Devices |  | 10,555 |  |  | 9,472 |
Total Reportable Segment Assets |  | $ | 27,374 |  |  | $ | 24,641 |
Cash and investments |  | 8,240 |  |  | 8,853 |
Goodwill and intangible assets |  | 29,872 |  |  | 29,755 |
All other (c) |  | 18,513 |  |  | 18,165 |
Total Assets |  | $ | 83,999 |  |  | $ | 81,414 |
(c) | As of June 30, 2025 and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total depreciation and additions to property, plant and equipment from reportable segments to the entity's consolidated amounts and segment assets + References No definition available. + Details
Name: | abt_ReconciliationOfDepreciationAdditionsToPropertyPlantAndEquipmentFromSegmentToConsolidatedAndAssetsBySegmentTableTextBlock
Namespace Prefix: | abt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration